UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 5.

Brüggemann, C; Kirchberger, M C; Goldinger, S M; Weide, B; Konrad, A; Erdmann, M; Schadendorf, D; Croner, R S; Krähenbühl, L; Kähler, K C; Hafner, C; Leisgang, W; Kiesewetter, F; Dummer, R; Schuler, G; Stürzl, M; Heinzerling, L (2017). Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab. Journal of Cancer Research and Clinical Oncology:Epub ahead of print.

Wagner, N B; Weide, B; Reith, M; Tarnanidis, K; Kehrel, C; Lichtenberger, R; Pflugfelder, A; Herpel, E; Eubel, J; Ikenberg, K; Busch, C; Holland-Letz, T; Naeher, H; Garbe, C; Umansky, V; Enk, A; Utikal, J; Gebhardt, C (2015). Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma. International Journal of Cancer, 137(11):2607-2617.

Weide, B; Eigentler, T K; Pflugfelder, A; Leiter, U; Meier, F; Bauer, J; Schmidt, D; Radny, P; Pföhler, C; Garbe, C (2011). Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up. Cancer Immunology, Immunotherapy, 60(4):487-493.

Weide, B; Carralot, J P; Reese, A; Scheel, B; Eigentler, T K; Hoerr, I; Rammensee, H G; Garbe, C; Pascolo, S (2008). Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. Journal of Immunotherapy, 31(2):180-188.

Weide, B; Garbe, C; Rammensee, H G; Pascolo, S (2008). Plasmid DNA- and messenger RNA-based anti-cancer vaccination. Immunology Letters, 115(1):33-42.

This list was generated on Fri Jul 28 10:01:53 2017 CEST.